Melbourne healthtech startup Everlab has raised $65 million in a Series A funding round led by Airtree Ventures. The round also saw participation from Plural, Left Lane Capital, b2venture and Australian Test cricket captain Pat Cummins.
The raise follows a $15 million seed round less than a year ago as the company looks to expand its preventative healthcare platform internationally and build what it describes as a more connected approach to primary care.
Founded in 2023, Everlab has developed a platform that combines diagnostics, clinicians, specialists, prescriptions, and wearable device data into a single system. The idea is to help patients identify health risks earlier and better manage their long-term health.
Everlab argues patients are often left navigating a healthcare system where medical records, specialist advice, diagnostic testing, and ongoing monitoring are spread across multiple providers and platforms.
“When care is organised around providers, it becomes fragmented across multiple touchpoints, data is scattered, and no one ends up being responsible for the complete picture,” Everlab CEO Marc Hermann told SmartCompany.
“Without a complete picture, providers are limited in the quality and level of personalised care they can deliver.”
The company’s app aims to provide a single view of a patient’s health history, bringing together test results, medical records, and ongoing care recommendations in one place.
“Our patient base reflects the broader Australian population, and earning their trust to hold decades of their health data is the foundation everything else runs on,” Dr Steven Lu, Everlab’s chief medical officer, said.
“Our goal is to cut a new path for primary care globally, proving that deep patient engagement and first-class preventative care don’t just improve outcomes, it reduces the lifetime cost of care for everyone.”
Everlab also said it makes extensive use of AI to analyse health information and support ongoing care planning, positioning itself as a technology layer that sits across a patient’s broader healthcare journey rather than replacing clinicians.
Hermann said technology plays a significant role in making preventative healthcare more accessible by helping clinicians work more efficiently and coordinate care across multiple providers.
“Preventive health has always been service-intensive, and that’s exactly what’s kept it out of reach for most people,” Hermann said.
“Productising it is how we change that, turning what was once a high-touch privilege into something accessible at scale.
“Technology improves both efficiency and the member experience. Through connected health records, asynchronous communication, and coordinated care planning, providers can work from the same information and contribute their expertise throughout a patient’s journey.”
The company says it now supports more than 20,000 patients across Australia and New Zealand, has completed more than 40,000 consultations, and processes more than 200,000 health reports each month.
According to Everlab, the platform integrates with more than 1,850 healthcare provider locations, works with more than 180 clinicians, and connects with more than 30 wearable devices.
The startup claims it has processed more than 21 million biomarker test results to date, with more than 25% of members receiving findings that had not previously been identified through the traditional healthcare system.
Hermann said the company is focused on identifying meaningful risks rather than simply increasing the volume of testing.
“We don’t believe in testing for the sake of testing. Every investigation should have a clear clinical rationale and the potential to inform meaningful decisions about a person’s care.”
He added that among Everlab members referred for colonoscopy, the company’s polyp detection rate is above 50%, which he said is well above expected performance standards.
Hermann also said that what truly matters is what happens after findings are identified, pointing to improvements in markers such as cholesterol, inflammation, fitness, and muscle mass among members.
“The real measure of success is what happens next,” he said. “We’re helping people improve the objective markers that matter.”
The fresh capital injection will be used to strengthen Everlab’s clinical and technology infrastructure and support international expansion, with the company identifying the UK as its next major market.
